Tristel plc

Tristel plc has a consistent record of revenue, profit and dividend growth as an AIM listed public company.  It is only one of a few businesses worldwide that specialises in infection prevention in human and animal healthcare and contamination control in industry.

The Investor Centre was last updated on 11/12/2018.  The information contained within it is disclosed in accordance with AIM Rule 26.  The Company is subject to the UK City Code on Takeovers and Mergers.

The Tristel story began in 1993 when the founding shareholders developed a proprietary chlorine dioxide formulation to be used for the disinfection of flexible endoscopes to replace glutaraldehyde.  At the time, glutaraldehyde was used universally throughout hospitals in the United Kingdom, and indeed worldwide, for the disinfection of heat sensitive medical instruments.  However, it was known to be toxic.

During the following decade Tristel captured significant market share in the United Kingdom hospital market.  In June 2005 Tristel plc was listed on the London Stock Exchange AIM market.

By this time the Company had developed a broader vision for the use of its chlorine dioxide chemistry and had developed products for the disinfection of a wide range of non-lumened and single lumened endoscopes and ultrasound probes, and also the disinfection of surfaces in hospitals.

A key milestone in Tristel’s development was the establishment of its manufacturing plant in Cambridgeshire in 2007.  The Company is an ISO 9001: 2015 and BS EN 13485:2016 certified manufacturer of disinfectants.

Today, Tristel serves the disinfection requirements of veterinary practices via its Anistel product range and those of clean rooms in healthcare and the life sciences industry via its Crystel product range. The Company operates a Class 6 cleanroom to manufacture sterile-packed disinfectant products.

The Company has subsidiaries in Germany, Poland, Switzerland, Russia, Hong Kong, China, Australia, New Zealand, Japan and USA, an associated company in Italy, and sells its products via distributors in more than thirty other countries.


Financial Performance

Board & Governance

Board of Directors

  • Francisco Soler
  • Paul Swinney
  • Liz Dixon
  • Paul Barnes
  • David Orr  
  • Tom Jenkins

Investor News

Investor Information

Listing Information

Business Summary: Manufacture and sale of products and systems addressing infection and contamination control in human and animal healthcare, pharmaceutical and personal care manufacturing plants and industrial water systems.

Sector: Healthcare equipment & services.

Index: Tristel plc shares are listed on the AIM (Alternative Investment Market). There are no other exchanges or trading platforms on which Tristel plc has applied or agreed to have any of its securities admitted or traded. There are no restrictions on the transfer of Tristel plc’s AIM securities.

Ticker Symbol: TSTL

Shares in Issue at 30 September 2018: 43,700,048  (Ord 1p)


Investor Relations Contacts

Welcome to Tristel
Please select from the following